Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8886)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Nov 6, 2017 (publication date) through Jan 3, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Nephrology
ISSN
2220-6124
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Almalki AH, Sadagah LF, Qureshi M, Maghrabi H, Algain A, Alsaeed A. Atypical hemolytic-uremic syndrome due to complement factor I mutation. World J Nephrol 2017; 6(6): 243-250 [PMID: 29226095 DOI: 10.5527/wjn.v6.i6.243] |
|---|---|
| URL: | https://www.wjgnet.com/2220-6124/full/v6/i6/243.htm |
| Number | Citing Articles |
| 1 |
Farhana Begum, Nida Khan, Stephanie Boisclair, Deepa A. Malieckal, David Chitty. Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria. American Journal of Therapeutics 2023; 30(3): e209 doi: 10.1097/MJT.0000000000001609
|
| 2 |
Omar K Abughanimeh, Muhamed Baljevic, Alex Nester. Novel Heterozygous Missense Variants in Diacylglycerol Kinase Epsilon and Complement Factor I: Potential Pathogenic Association With Atypical Hemolytic Uremic Syndrome. Cureus 2024; doi: 10.7759/cureus.52633
|
| 3 |
Daigo Nakazawa. Targeting complement in kidney transplantation: Therapeutic approaches based on preclinical and experimental evidence. Transplantation Reviews 2025; 39(1): 100887 doi: 10.1016/j.trre.2024.100887
|
| 4 |
Yulia V. Lavrishcheva, Alexander A. Yakovenko, Dmitrii A. Kudlai. The experience of using the Russian biosimilar of the original drug eculizumab for the treatment of patients with atypical hemolytic-uremic syndrome. Terapevticheskii arkhiv 2020; 92(6): 76 doi: 10.26442/00403660.2020.06.000649
|